FOLLOWING several months of comprehensive due diligence and negotiation, Mundipharma has announced the acquisition of specialist pharmaceutical company, Tolmar Australia, supplementing its own oncology protfolio by including exclusive distribution rights for the oncology medication Eligard and Bi-Eligard (leuprorelin acetate) in Australia and New Zealand.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Feb 18
